A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin-epinephrine injectable gel plus paclitaxel and carboplatin in treating patients who have recurrent head and neck cancer.

Start Date01 Nov 2000

Sponsor / Collaborator

Matrix Pharmaceutical, Inc.

100 Clinical Results associated with Cisplatin/Epinephrine

100 Translational Medicine associated with Cisplatin/Epinephrine

100 Patents (Medical) associated with Cisplatin/Epinephrine

224

Literatures (Medical) associated with Cisplatin/Epinephrine

08 Mar 2024·Alternative therapies in health and medicine

Related Factors of CRKP Infection in Neurosurgery and Comparison of Therapeutic Effects of Tigecycline Versus Polymyxin B for CRKP Infection.

Article

Author: Li, Yang ; Wang, Shiyong ; Yu, Haohui ; Li, Ning ; Liu, Shengming ; Feng, Yongjian ; Chen, Huixuan

ObjectiveThis paper aimed to identify the factors related to Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection in neurosurgical patients, and to compare the therapeutic effects of tigecycline versus polymyxin B against CRKP infection, so as to provide a reliable reference for neurosurgery in future prevention and treatment of CRKP infection.MethodsOne hundred and fifty cases of KPN treated in the neurosurgery department of our hospital from January 1, 2019 to December 31, 2021 were selected, 50 of which were found to be infected with CRKP and the other 100 were detected with carbapenem-sensitive Klebsiella pneumoniae (CSKP) by culture, analysis of factors associated with infection with CRKP. Subsequently, CRKP-infected patients were randomized into a group treated with Ti (group Ti) and a group treated with PB (group PB). The clinical efficacy, bacterial clearance, adverse reactions, and pre- and post-treatment hepatorenal function were comparatively analyzed.ResultsBased on the Logistic regression analysis, tracheal intubation (or mechanical ventilation), combination of multiple underlying diseases, presence of impaired consciousness, and use of carbapenem antibiotics are independent risk factors for CRKP infection (P < .05). Ti and PB groups had no evident differences in clinical efficacy and bacterial clearance (P > .05); however, Ti group presented a worse hepatorenal function and a higher incidence of adverse reactions than PB group (P < .05).ConclusionsTracheal intubation (or mechanical ventilation), multiple underlying diseases, consciousness disturbance, and use of carbapenem antibiotics are related factors affecting CRKP infection in neurosurgical patients. Both Ti and PB have excellent therapeutic efficacy, but the former has more obvious toxicity and side effects.

01 Feb 2024·Cell Reports Medicine

TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS

Article

Author: Yan, Jing ; Bading, Hilmar ; Hellwig, Andrea ; Wang, Yu Meng

Toxic signaling by extrasynaptic NMDA receptors (eNMDARs) is considered an important promoter of amyotrophic lateral sclerosis (ALS) disease progression. To exploit this therapeutically, we take advantage of TwinF interface (TI) inhibition, a pharmacological principle that, contrary to classical NMDAR pharmacology, allows selective elimination of eNMDAR-mediated toxicity via disruption of the NMDAR/TRPM4 death signaling complex while sparing the vital physiological functions of synaptic NMDARs. Post-disease onset treatment of the SOD1^G93A ALS mouse model with FP802, a modified TI inhibitor with a safe pharmacology profile, stops the progressive loss of motor neurons in the spinal cord, resulting in a reduction in the serum biomarker neurofilament light chain, improved motor performance, and an extension of life expectancy. FP802 also effectively blocks NMDA-induced death of neurons in ALS patient-derived forebrain organoids. These results establish eNMDAR toxicity as a key player in ALS pathogenesis. TI inhibitors may provide an effective treatment option for ALS patients.

01 Feb 2024·iScience

Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally

Article

Author: Bravo-Robles, Laura ; Bıçakcıoğlu, Gülce ; Mata-Martínez, Pablo ; Del Fresno, Carlos ; Fernández-Pascual, Jaime ; López-Collazo, Eduardo ; Zapata-Fernández, Gabriela ; Bergón-Gutiérrez, Marta ; Minute, Luna ; Aguiló, Nacho ; Terrón, Verónica

Trained immunity (TI) represents a memory-like process of innate immune cells. TI can be initiated with various compounds such as fungal β-glucan or the tuberculosis vaccine, Bacillus Calmette-Guérin. Nevertheless, considering the clinical applications of harnessing TI against infections and cancer, there is a growing need for new, simple, and easy-to-use TI inducers. Here, we demonstrate that heat-killed Mycobacterium tuberculosis (HKMtb) induces TI both in vitro and in vivo. In human monocytes, this effect represents a truly trained process, as HKMtb confers boosted inflammatory responses against various heterologous challenges, such as lipopolysaccharide (Toll-like receptor [TLR] 4 ligand) and R848 (TLR7/8 ligand). Mechanistically, HKMtb-induced TI relies on epigenetic mechanisms in a Syk/HIF-1α-dependent manner. In vivo, HKMtb induced TI when administered both systemically and intranasally, with the latter generating a more robust TI response. Summarizing, our research has demonstrated that HKMtb has the potential to act as a mucosal immunotherapy that can successfully induce trained responses.

100 Deals associated with Cisplatin/Epinephrine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	US	Novartis AG	-
Breast Cancer	Phase 2	-	Novartis AG	-
Breast Cancer	Phase 2	-	Novartis Pharma AG	-
Lung Cancer	Phase 2	-	Novartis Pharma AG	-
Lung Cancer	Phase 2	US	Novartis AG	-
Sarcoma	Phase 2	-	Novartis AG	-
Sarcoma	Phase 2	US	Novartis AG	-
Sarcoma	Phase 2	-	Novartis Pharma AG	-
Lung Cancer	Preclinical	-	Novartis AG	-
Melanoma	Preclinical	US	Novartis AG	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2018	Not Applicable	Malignant Pleural Mesothelioma	27	Ganetespib	(nxemxdqhnm): hazard ratio = 0.32 (95% CI, 0.11 - 0.95), P-Value = 0.04	-	25 Sep 2018
				Pemetrexed and Cisplatin/Carboplatin Chemotherapy
WCLC2015	Not Applicable	Extensive stage Small Cell Lung Cancer	62	Irinotecan/cisplatin (IP)	(nazivgukti) = dexhtzyiyd pybbznmpwv (xrheubvabo ) View more	-	08 Sep 2015
				Etoposide/cisplatin (EP)	(nazivgukti) = vheinpieho pybbznmpwv (xrheubvabo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis